We are AliveDx.
Products & Services
Our innovative solutions – Alba, our blood bank reagents portfolio, and MosaiQ, one of the first multiplexing and multimodality automated testing platforms – are revolutionizing clinical diagnostics worldwide. Our products are built with the patient in mind and designed to make labs more efficient and clinical decision-making more effective.
Driven to Provide Solutions
AliveDx’s ability to envision what’s possible in diagnostics is grounded in our 30-year heritage in immunohematology and driven by our longstanding passion for understanding and addressing customer needs.
MosaiQ®
Our MosaiQ solution is designed to shorten time-to-diagnosis for patients by providing faster in-vitro test results. As an easy-to-use single solution, the platform performs multiple tests and gives maximum flexibility to laboratorians and clinicians.
Alba
The Alba manual reagent product line is backed by expert technical support and reliable customer service. Join our satisfied customers and see the difference that Alba can make in your laboratory.
Ready to Innovate for Life?
Discover how our solutions help.
Trending Topics
Recent press, briefings and insights helping you stay informed on AliveDx news.
-
AliveDx Earns Great Place To Work Certification™ in its 3 sites: Switzerland, UK and US
AliveDx is proud to be Certified™ by Great Place To Work®. The prestigious award is based entirely on what current employees say about their experience working at AliveDx. Great Place To Work® is the global authority on workplace culture, employee
-
AliveDx Suisse S.A. and Warba Medical Supplies Co. W.L.L sign two strategic distribution agreements in Kuwait
AliveDx Suisse S.A. and Warba Medical Supplies Co. W.L.L. have signed two strategic distribution agreements, which will enable Warba Medical Supplies to distribute the MosaiQ® and LumiQ® solutions in Kuwait. The distribution agreements take effect immediately. This partnership underscores AliveDx’s
-
AliveDx Suisse S.A. and Bio-Strategy, part of DKSH Group, sign a distribution agreement for Australia and New Zealand
AliveDx Suisse S.A. and Bio-Strategy, part of DKSH Group, have signed a distribution agreement, which will enable Bio-Strategy to distribute the LumiQ™ solution in Australia and New Zealand. The distribution agreement takes effect immediately. This partnership underscores AliveDx’s dedication to
-
Join us at EuroMedLab 2025
We are excited to announce our participation in the upcoming EuroMedLab Congress in Brussels, Belgium, from 19-22 May 2025. Visit us at booth #245 to learn more about our MosaiQ® and LumiQ™ innovative, turnkey, fully automated autoimmune diagnostic solutions. The
-
AliveDx announces US FDA 510(k) submission for MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) multiplex microarray
Eysins, Switzerland, 3 April 2025 – Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex® Connective Tissue Diseases (CTDplus) microarray. The MosaiQ AiPlex CTDplus multiplex assay, which received
-
AliveDx Suisse S.A. and Disera Tibbi Malzeme Lojistik. san. Tic. A.S sign Distribution Agreement in Türkiye
AliveDx Suisse S.A. and Disera Tibbi Malzeme Lojistik. san. Tic. A.S have signed a distribution agreement, which will enable Disera to distribute the MosaiQ® and LumiQ™ solutions in Türkiye. The distribution agreement takes effect immediately. This strategic partnership with an
